Drug Trial Radar · NCT01872598
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
721
Actual
Start
Jan 2012
Primary completion
Dec 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.
Conditions
- Alzheimer Disease
Interventions
MasitinibDrug
PlaceboDrug
Standard of careDrug
stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ADCS-ADLTime frame: 24 weeks
- ADAS-CogTime frame: 24 weeks
Locations
6 sites in 6 countries. Site status is shown where the registry gives one.
MHAT Sveta Marina
Varna, Bulgaria
General Hospital of Thessaloniki
Thessaloniki, Greece
Centrum Zdrowia Stołeczna 7
Bialystok, Poland
Spitalul Universitar de Urgenta Elias
Bucharest, Romania
Hospital Universitario Ramón y Cajal
Madrid, Spain
Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov
Dnipropetrovsk, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.